Trial Search Results
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
The purpose of this study is to characterize how safe the study drug is when given alone or in combination with Keytruda. We also measure how participants' cancer is responding to these medications
Stanford is currently not accepting patients for this trial.
Acerta Pharma BV
Collaborator: Merck Sharp & Dohme Corp.
- Drug: Acalabrutinib
- Drug: acalabrutinib and pembrolizumab combination
- Women ≥ 18 years of age.
- Histologically confirmed ovarian epithelial (including fallopian tube and primary
- Progression of disease after the most recent anticancer treatment. At least 1 prior
chemotherapy regimen must have included a taxane.
- Platinum-sensitive ovarian cancer defined by recurrence or progression of disease > 6
AND < 24 months after completion of the most recent platinum-based therapy.
- Measurable disease as defined by RECIST 1.1.
- ECOG performance status of 0 or 1.
- Completion of all therapy for the treatment of cancer 2 weeks before the start of
study therapy and recovered.
- Evidence of platinum-refractory ovarian cancer defined as recurrence or progression
during the first 6 cycles of or < 6 months after the beginning of first-line platinum
- Evidence of platinum-resistant ovarian cancer defined as recurrence or progression
within 6 months after completing the most recent platinum-based therapy.
- More than 3 prior lines of cytotoxic chemotherapy for ovarian cancer.
- Prior malignancy (other than ovarian cancer), except for adequately treated basal cell
or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the
subject has been disease free for ≥ 2 years or which will not limit survival to < 2
- Breastfeeding and pregnant.
- Known central nervous system metastases and/or carcinomatous meningitis.
- Subjects with active cardiovascular disease not medically controlled or those who have
had myocardial infarction in the past 6 months..
- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
resection of the stomach or small bowel, symptomatic inflammatory bowel disease,
partial or complete bowel obstruction.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study